Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...

A new, long-acting injectable to prevent HIV infection could be a “game-changer” in ending the AIDS epidemic, if all who ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...